BioLife Solutions, Inc. (BLFS)

BioLife Solutions, Inc. is trading at $38.61, up 0.00% on the session. The 50 day average sits at $35.70 and the 200 day at $26.62, which puts the stock in a uptrend. RSI is at 60.6, which reads as strong, and MACD is bearish crossover. Volume is below average.

The nearest support is around $34.38 with resistance near $39.76, so that band frames the current range. Average daily movement is roughly $1.09, or about 2.8% of the share price, which is what any stop placement has to allow for. The overall health score of 77 out of 100 combines a trend score of 100, momentum of 59 and a risk score of 65.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.